Therapeutic drugs and treatment of SARS-CoV-2

doi:10.12092/j.issn.1009-2501.2020.06.015

Abstract

Abstract: Novel coronavirus pneumonia caused by the SARS-CoV-2 appeared in Wuhan, China in December 2019. The virus spread rapidly across the country and resulted in the infection of more than 80000 people by March 8,2020. This paper introduces the data of tested drugs in vitro, in animal and in clinical trials marketed and in research, in hoping of providing reference for the prevention and control of SARS-CoV-2.

Key words: SARS-CoV-2, research of new drug, research and development ideas, clinical trials

CLC Number:

R979.4

HAO Yuqi, XIAO Yao, WANG Qian, JIANG Xingxu. Therapeutic drugs and treatment of SARS-CoV-2[J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2020, 25(6): 716-720.

References 28

[1]	Lu R, Zhao X, Li J, et al. Genomic characterisation and epidemiology of 2019 novel coronavirus: implications for virus origins and receptor binding [J].The Lancet, 2020, 395(10224): 565-574.
[2]	Jiang S, Shi Z, Shu Y, et al. A distinct name is needed for the new coronavirus [J]. The Lancet, 2020, 395(10228): 949.
[3]	Wu Y, Ho W, Huang Y, et al. SARS-CoV-2 is an appropriate name for the new coronavirus [J]. The Lancet, 2020, 395(10228): 949-950.
[4]	Tang X, Wu C, Li X, et al. On the origin and continuing evolution of SARS-CoV-2 [J]. Natl Sci Rev, 2020, 10(10): 1-12.
[5]	刘奇, 夏帅, 姜世勃. 抗新型冠状病毒2019-nCoV新药的研发 [J]. 中国临床药理学与治疗学, 2020, 25(3): 241-245.
[6]	Han DP, Penn-Nicholson A, Cho MW. Identification of critical determinants on ACE2 for SARS-CoV entry and development of a potent entry inhibitor [J]. Virol, 2006, 350(1): 15-25.
[7]	Hoffmann M, Kleine-Weber H, Schroeder S, et al. SARS-CoV-2 cell entry depends on ACE2 and TMPRSS2 and Is blocked by a clinically proven protease inhibitor [J]. Cell, 2020, 182(2): 271-280.
[8]	Jeffers SA, Tusell SM, Gillim-Ross L, et al. CD209L (L-SIGN) is a receptor for severe acute respiratory syndrome coronavirus [J]. Proc Natl Acad Sci U S A, 2004,101(44): 15748-15753.
[9]	Shirato K, Kawase M, Matsuyama S. Middle east respiratory syndrome coronavirus infection mediated by the transmembrane serine protease TMPRSS2 [J]. J Virol, 2013, 87(23): 12552-12561.
[10]	Zhou Y, Vedantham P, Lu K, et al. Protease inhibitors targeting coronavirus and filovirus entry [J]. Antiviral Res, 2016, 116: 76-84.
[11]	Hatesuer B, Bertram S, Mehnert N, et al. Tmprss2 is essential for influenza H1N1 virus pathogenesis in mice [J]. Plos Pathogens, 2013, 9(12): e1003774.
[12]	Jorquera PA, Mathew C, Pickens JA, et al. Verdinexor (KPT-335), a selective inhibitor of nuclear export, reduces respiratory syncytial virus replication in vitro [J]. J Virol, 2018, 93(4): 1-17.
[13]	Rossignol JF. Nitazoxanide: A first-in-class broad-spectrum antiviral agent [J]. Antiviral Res, 2014, 110: 94-103.
[14]	Javier Carbajo-Lozoya, Yue Ma-Lauer, Miroslav Maleevi, et al.Human coronavirus NL63 replication is cyclophilin A-dependent and inhibited by non-immunosuppressive cyclosporine A-derivatives including Alisporivir [J]. Virus Res, 2014, 184: 44-53.
[15]	Dyall J, Coleman CM, Hart BJ, et al.Repurposing of clinically developed drugs for treatment of middle east respiratory syndrome coronavirus infection [J]. Antimicrob Agents Chemother, 2014, 58(8): 4885-4893.
[16]	Holshue ML, DeBolt C, Lindquist S, et al. First case of 2019 novel coronavirus in the united states [J]. N Engl J Med, 2020. Doi:10.1056/NEJMoa2001191.
[17]	Cohen J. Can an anti-HIV combination or other existing drugs outwit the new coronavirus [J/OL]? Science,2020.https://www.sciencemag.org/news/2020/01/can-anti-hiv-combination-or-other-existing-drugs-outwit-new-coronavirus.
[18]	蓝巧帅, 夏帅, 周洁, 等. 新型冠状病毒SARS-CoV-2感染治疗中的"老药新用" [J]. 中国临床药理学与治疗学, 2020, 25(2): 126-134.
[19]	Wang M, Cao R, Zhang L, et al. Remdesivir and chloroquine effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in vitro [J]. Cell Res, 2020, 30(10223): 269-271.
[20]	Richardson P, Griffin I, Tucker C, et al. Baricitinib as potential treatment for 2019-nCoV acute respiratory disease [J]. The Lancet, 2020, 395(10223):e30-e31.
[21]	Zumla A, Chan JF, Azhar EI, et al. Coronaviruses - drug discovery and therapeutic options [J]. Nat Rev Drug Discov, 2016, 15(5): 327-347.
[22]	Guangdi Li, Erik De Clercq. Therapeutic options for the 2019 novel coronavirus (2019-nCoV) [J]. Nat rev Drug Discov, 2020,19(3): 149-150.
[23]	Hart BJ, Dyall J, Postnikova E, et al. Interferon-beta and mycophenolic acid are potent inhibitors of Middle East respiratory syndrome coronavirus in cell-based assays [J]. J General Viro, 2014, 95: 571-577.
[24]	Al-Tawfiq JA, Momattin H, Dib J, et al. Ribavirin and interferon therapy in patients infected with the Middle East respiratory syndrome coronavirus: an observational study [J]. Int J Infect Dis, 2014, 20: 42-46.
[25]	Nukoolkarn V, Lee VS, Malaisree M, et al. Molecular dynamic simulations analysis of ritronavir and lopinavir as SARS-CoV 3CLpro inhibitors [J]. J Theo Biolog, 2008, 254(4): 861-867.
[26]	Chen F, Chan KH, Jiang Y, et al. In vitro susceptibility of 10 clinical isolates of SARS coronavirus to selected antiviral compounds [J]. J Clin Virol, 2004, 31(1): 69-75.
[27]	Weng JR, Lin CS, Lai HC, et al. Antiviral activity of sambucus formosananakai ethanol extract and related phenolic acid constituents against human coronavirus NL63 [J]. Virus Res, 2019, 273: 197767.
[28]	观察者网. 中科院发现30种药物可能对新型冠状病毒有效[N]. 观察者网, 2020.https://www.guancha.cn/politics/2020_01_25_533108.shtml?s=zwytt.